International ASSWGoHIVC, Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Di Mascio M et al. Towards an HIV cure: a global scientific strategy. Nature reviews Immunology. 2012;12(8):607–14.
NIAID Strategic Plan. [http://www.niaid.nih.gov/about/whoweare/planningpriorities/documents/niaidstrategicplan2013.pdf]
Research Toward a Cure Trials June 8, 2015. [http://www.treatmentactiongroup.org/cure/trials]
Tucker JD, Rennie S, Social, Ethical Working Group on HIVC. Social and ethical implications of HIV cure research. Aids. 2014;28(9):1247–50.
Global Investment in HIV Cure Research and Development 2014 [http://www.iasociety.org/Web/WebContent/File/Towards_and_HIV_Cure_Tracking_Paper_2014.pdf]
NIH. FY 2014 Trans-NIH Plan for HIV-Related Research. Bethesda: NIH; 2014.
World´s leading HIV/AIDS Scientists and Stakeholders to gather in Washington D.C. to discuss Global Alliance on HIV Cure research [http://www.webcitation.org/6XKxzBPGa]
US-China Program for Research Toward a Cure for HIV/AIDS. Washington, DC. R01 RFA. July 16th, 2014. [http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-057.html].
Ananworanich J, Chomont N, Fletcher JLK, et al. Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. Journal of Virus Eradication. 2015;1:116–22.
International AIDS Society, AVAC, HIV Vaccines & Microbicides Resource Tracking Working Group. Global Investment in HIV Cure Research and Development in 2013: Moving towards greater global investment and collaboration to accelerate research towards a cure for HIV. July 2014.[https://www.iasociety.org/Web/WebContent/File/HIV_Cure_Resource_Tracking_Paper_2013.pdf]
amfAR Announces $100 Million Investment Strategy Aimed at Curing HIV [http://www.webcitation.org/6XKzxZsIv]
UNC-Chapel Hill and GSK announce novel partnership to accelerate search for HIV cure [http://www.webcitation.org/6YVWX1JFU]
Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. Aids. 2003;17(13):1871–9.
Ananworanich J, Dube K, Chomont N. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Current opinion in HIV and AIDS. 2015;10(1):18–28.
Yerly S, Kaiser L, Perneger TV, Cone RW, Opravil M, Chave JP, Furrer H, Hirschel B, Perrin L. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. Aids. 2000;14(3):243–9.
McNearney T, Hornickova Z, Markham R, Birdwell A, Arens M, Saah A, Ratner L. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(21):10247–51.
Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, Posada JG, Kardava L, O'Shea MA, Kottilil S et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood. 2010;116(25):5571–9.
Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, Sontag G, Sewell AK, Phillips RE. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(7):3382–7.
Deeks SGLS, Havlir DV. The End of AIDS: HIV Infection as a Chronic Disease. Lancet. 2013;382:1525–33.
Rosenberg NE, Pilcher CD, Busch MP, Cohen MS. How can we better identify early HIV infections? Current opinion in HIV and AIDS. 2015;10(1):61–8.
Wawer MJGR, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. Journal of Infectious Disease. 2005;191:1403–9.
Buzon MJ, Martin-Gayo E, Pereyra F, et al. Long-term antiretroviral treatment initiated in primary HIV-1 infection affects the size, composition and decay kinetics of the reservoir of HIV-1 infected CD4 T cells. J Virol. 2014;88(17):10056–65.
Delwart E, Magierowska M, Royz M, Foley B, Peddada L, Smith R, Heldebrant C, Conrad A, Busch M. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. Aids. 2002;16(2):189–95.
Rieder P, Joos B, von Wyl V, Kuster H, Grube C, Leemann C, Boni J, Yerly S, Klimkait T, Burgisser P et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS. 2010;24(8):1177–83.
Remien RH, Higgins JA, Correale J, Bauermeister J, Dubrow R, Bradley M, Steward WT, Seal DW, Sikkema KJ, Kerndt PR et al. Lack of understanding of acute HIV infection among newly-infected persons-implications for prevention and public health: The NIMH Multisite Acute HIV Infection Study: II. AIDS and behavior. 2009;13(6):1046–53.
Kelly JA, Morin SF, Remien RH, Steward WT, Higgins JA, Seal DW, Dubrow R, Atkinson JH, Kerndt PR, Pinkerton SD et al. Lessons learned about behavioral science and acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: V. AIDS and behavior. 2009;13(6):1068–74.
Persaud D, Gay H, Ziemniak C, Chen YH, Piatak Jr M, Chun TW, Strain M, Richman D, Luzuriaga K. Absence of detectable HIV-1 viremia after treatment cessation in an infant. The New England journal of medicine. 2013;369(19):1828–35.
Persaud D, Palumbo PE, Ziemniak C, Hughes MD, Alvero CG, Luzuriaga K, Yogev R, Capparelli EV, Chadwick EG. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. Aids. 2012;26(12):1483–90.
Rainwater-Lovett K, Luzuriaga K, Persaud D. Very early combination antiretroviral therapy in infants: prospects for cure. Current opinion in HIV and AIDS. 2015;10(1):4–11.
Piot P, Abdool Karim SS, Hecht R, Legido-Quigley H, Buse K, Stover J, Resch S, Ryckman T, Mogedal S, Dybul M et al. Defeating AIDS--advancing global health. Lancet. 2015;386(9989):171–218.
Katz I, Glandon D, Wong W, Kargbo B, Ombam R, Singh S, Ramsammy L, Tal-Dia A, Seck I, Osika JS. Lessons learned from stakeholder-driven sustainability analysis of six national HIV programmes. Health Policy Plan. 2014;29(3):379–87.
Chu CE, Wu F, He X, Ma Q, Cheng Y, Cai W, Volberding P, Tucker JD. Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China. AIDS research and human retroviruses. 2015;31(1):78–84.
2BeatHIV Campaign [www.2BeatHIV.org] Chapel Hill, NC, USA.
Tucker JD, Volberding PA, Margolis DM, Rennie S, Barre-Sinoussi F. Words matter: Discussing research towards an HIV cure in research and clinical contexts. Journal of acquired immune deficiency syndromes. 2014;67(3):e110–111.
Rennie S, Siedner M, Tucker JD, Moodley K. The ethics of talking about 'HIV cure'. BMC Med Ethics. 2015;16:18.
Lo Y, Chu C, Ananworanich J, Excler J, Tucker JD. Stakeholder engagement in HIV cure research: Lessons learned from other HIV interventions and the way forward. AIDS Patient Care & STDs. 2015;29(7):389–99.
MacNeil JM, Anderson S. Beyond the dichotomy: linking HIV prevention with care. Aids. 1998;12 Suppl 2:S19–26.